During the past decade, HCA Midwest Division conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 14 clinical trials were completed, i.e. on average, 37.8% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 13 clinical trials were completed. i.e. 68.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "HCA Midwest Division" #1 sponsor was "Hoffmann-La Roche" with 11 trials, followed by "Bristol-Myers Squibb" with 4 trials sponsored, "SCRI Development Innovations, LLC" with 3 trials sponsored, "Seagen Inc." with 3 trials sponsored and "Celgene" with 3 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "HCA Midwest Division" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Acerta Pharma, LLC" with 1 trials as a collaborator, "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator and "Blueprint Medicines Corporation" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "HCA Midwest Division" are "Breast Cancer" (4 trials), "Metastatic Breast Cancer" (3 trials), "Leukemia, Myeloid, Acute" (2 trials), "Multiple Myeloma" (2 trials) and "Non-small Cell Lung Cancer" (2 trials). Many other conditions were trialed in "HCA Midwest Division" in a lesser frequency.

Most popular intervention types in "HCA Midwest Division" are "Drug" (38 trials), "Other" (4 trials), "Biological" (2 trials), "Procedure" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Atezolizumab" (7 trials), "Cyclophosphamide" (5 trials), "Doxorubicin" (4 trials) and "Nivolumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "HCA Midwest Division" are 37 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "HCA Midwest Division". undefined are not yet recruiting, 7 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in HCA Midwest Division, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in HCA Midwest Division, 1 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".

HCA Midwest Division has several departments that took part in Clinical trials: "Kansas City Heart Rhythm Institute" - 37 trials, "Kansas City Cancer Centers - South" - 18 trials